Article
Surgery
Claire Temple-Oberle, Christine Nicholas, Priscila Rojas-Garcia
Summary: This article introduces the learning objectives of melanoma management, including appropriate margins for in situ and invasive disease, reconstructive options for wide excision defects such as the keystone flap, digit-sparing alternative for subungual melanoma, personalized risk estimates for sentinel node biopsy using predictive nomograms, and minimally invasive modalities for effective control of in-transit recurrences.
PLASTIC AND RECONSTRUCTIVE SURGERY
(2023)
Review
Cell Biology
Emilio Francesco Giunta, Gianluca Arrichiello, Marcello Curvietto, Annalisa Pappalardo, Davide Bosso, Mario Rosanova, Anna Diana, Pasqualina Giordano, Angelica Petrillo, Piera Federico, Teresa Fabozzi, Sara Parola, Vittorio Riccio, Brigitta Mucci, Vito Vanella, Lucia Festino, Bruno Daniele, Paolo Antonio Ascierto, Margaret Ottaviano
Summary: Cutaneous melanoma is a deadly disease, but recent progress has improved survival rates, necessitating the need for new therapeutic approaches. Epigenetics plays a crucial role in melanoma and may serve as new targets for future treatments.
Review
Cell Biology
Akihiko Yoshida
Summary: This review provides an update on the key clinicopathological and molecular characteristics of NUT carcinoma and thoracic SMARCA4-deficient undifferentiated tumour, as well as the controversies and strategies in their diagnosis.
Review
Cell Biology
Valeria Castelli, Andrea Lombardi, Emanuele Palomba, Giorgio Bozzi, Riccardo Ungaro, Laura Alagna, Davide Mangioni, Antonio Muscatello, Alessandra Bandera, Andrea Gori
Summary: ICIs play a crucial role in restoring the immune exhaustion state of T lymphocytes in cancer treatment; Their potential use and impact on safety and effectiveness in HIV-infected individuals are being explored; The administration of ICIs may influence opportunistic infections.
Review
Immunology
Chi Chiu Mok
Summary: Combination therapy of different drugs may improve the efficacy of treatment for LN, but it also increases the risk of infections. There is still controversy regarding the timing and choice of drugs for combination therapy, partly due to cost-effectiveness.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
(2023)
Review
Medicine, General & Internal
Alessandro Nepote, Gianluca Avallone, Simone Ribero, Francesco Cavallo, Gabriele Roccuzzo, Luca Mastorino, Claudio Conforti, Luca Paruzzo, Stefano Poletto, Fabrizio Carnevale Schianca, Pietro Quaglino, Massimo Aglietta
Summary: About 50% of melanomas have a BRAF mutation, with 10% of these having a V600K mutation. No specific studies have been conducted to establish a clinical and therapeutic gold standard for V600K melanoma patients. However, recent findings suggest that V600K melanoma is less dependent on the ERK/MAPK pathway and can be effectively treated with BRAF and MEK inhibitors or anti-checkpoint blockades. Nonetheless, V600K melanoma remains a medical need and is associated with poor prognosis.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Pharmacology & Pharmacy
I. Anestopoulos, S. Kyriakou, V. Tragkola, I. Paraskevaidis, E. Tzika, M. Mitsiogianni, M. V. Deligiorgi, G. Petrakis, D. T. Trafalis, S. Botaitis, A. Giatromanolaki, M. I. Koukourakis, R. Franco, A. Pappa, M. I. Panayiotidis
Summary: This review article discusses current therapeutic options in melanoma treatment, focusing on distinct epigenetic alterations and how specific drug compounds can reverse these changes. Abnormal epigenetic mechanisms have been found to be associated with the onset, progression, and drug resistance of melanoma.
PHARMACOLOGY & THERAPEUTICS
(2022)
Review
Oncology
Allison Betof Warner, Pippa G. Corrie, Omid Hamid
Summary: Adoptive cell therapy with tumor-infiltrating lymphocytes (TIL) has shown durable responses in patients with advanced melanoma, but it is not yet approved by any regulatory agency. TIL therapy involves harvesting patient-specific T cells from tumors, expanding them ex vivo, and re-infusing them back into the patient. Objective response rates of 30% to 50% have been observed in heavily pretreated patients, including those who have progressed after other treatments. Improvements in patient selection, TIL production, and efficacy are currently being explored.
CLINICAL CANCER RESEARCH
(2023)
Review
Medicine, General & Internal
Dimitrios Nasioudis, Erin M. George, Janos L. Tanyi
Summary: Approximately 10-25% of patients with locally advanced cervical cancer have metastases to the para-aortic lymph nodes. PET-CT and surgical staging are important for accurate treatment planning, as imaging techniques can have high false negative rates. However, the impact of para-aortic lymphadenectomy on patient outcomes is still controversial.
Article
Oncology
Simon F. Merz, Philipp Jansen, Ricarda Ulankiewicz, Lea Bornemann, Tobias Schimming, Klaus Griewank, Zuelal Cibir, Andreas Kraus, Ingo Stoffels, Timo Aspelmeier, Sven Brandau, Dirk Schadendorf, Eva Hadaschik, Gernot Ebel, Matthias Gunzer, Joachim Klode
Summary: This study utilized LSFM technology to comprehensively analyze SLNs of melanoma patients, revealing metastases undetectable by routine histopathological assessment and improving the accuracy of detection and localization of metastatic cancer, potentially providing additional therapeutic options for patients.
EUROPEAN JOURNAL OF CANCER
(2021)
Review
Pathology
Cristina Diaz del Arco, Luis Ortega Medina, Lourdes Estrada Munoz, Soledad Garcia Gomez de las Heras, M. Jesus Fernandez Acenero
Summary: There are controversies surrounding LN assessment in gastric cancer, with alternative prognostic methods showing better accuracy than the TNM system. The value of SLN biopsy and LNMI in GC remains unclear, while ECE and TDs have been identified as independent prognostic factors for survival.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY
(2021)
Article
Oncology
ChuanLiang Cui, Bin Lian, XiaoShi Zhang, Di Wu, Ke Li, Lu Si, Yue Yang, Hui Tian, Li Zhou, ZhiHong Chi, XiNan Sheng, Yan Kong, LiLi Mao, Xuan Wang, Xue Bai, XieQiao Yan, SiMing Li, Jie Dai, BiXia Tang, Xiaoting Wei, Jeffrey E. Gershenwald, Charles M. Balch, Jun Guo
Summary: Based on a study of 1814 MuM patients, researchers have proposed a staging system for mucosal melanoma that incorporates all anatomical primary tumor sites and can be used to guide the design of clinical trials.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Dermatology
Chryssoula Papageorgiou, Zoe Apalla, Sofia-Magdalini Manoli, Konstantinos Lallas, Efstratios Vakirlis, Aimilios Lallas
Summary: Cancer staging is crucial for determining the extent and location of cancer in the body, impacting prognosis and treatment decisions. Melanoma staging is based on the TNM classification system, with multiple factors considered for determining the stage.
DERMATOLOGY PRACTICAL & CONCEPTUAL
(2021)
Review
Psychiatry
Kala Chinnaswamy, Dominic M. DeMarco, George T. Grossberg
Summary: Doll therapy (DT) shows promising benefits in managing behavioral symptoms of major neurocognitive disorder (MNCD), but research on its utility is limited and primarily consists of small, unrepresentative sample populations. Larger and more diverse studies are needed to better understand the effectiveness and potential ethical concerns of this therapy.
ANNALS OF CLINICAL PSYCHIATRY
(2021)
Article
Oncology
Alexander C. J. van Akkooi, Dirk Schadendorf, Alexander M. M. Eggermont
Summary: Sentinel lymph node biopsy (SLNB) was introduced in the 1990s to identify patients who may benefit from completion lymph node dissection. SLNB staging has been found to be the best for staging melanoma. Adjuvant systemic therapy and biomarkers are emerging, which might reduce the need for SLNB staging in the future.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Julia Eckardt, Christopher Schroeder, Peter Martus, Sorin Armeanu-Ebinger, Olga Kelemen, Axel Gschwind, Irina Bonzheim, Thomas Eigentler, Teresa Amaral, Stephan Ossowski, Olaf Riess, Lukas Flatz, Claus Garbe, Andrea Forschner
Summary: BRAF mutation status and tumor mutational burden (TMB) were found to be independent predictive factors for relapse-free survival (RFS) in melanoma patients receiving adjuvant anti-PD-1 therapy. Patients with BRAF V600E/K mutation and high TMB had the best outcomes. A classification based on BRAF mutation status and TMB is proposed to predict RFS in these patients.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Jeffrey S. Weber, Dirk Schadendorf, Michele Del Vecchio, James Larkin, Victoria Atkinson, Michael Schenker, Jacopo Pigozzo, Helen Gogas, Stephane Dalle, Nicolas Meyer, Paolo A. Ascierto, Shahneen Sandhu, Thomas Eigentler, Ralf Gutzmer, Jessica C. Hassel, Caroline Robert, Matteo S. Carlino, Anna Maria Di Giacomo, Marcus O. Butler, Eva Munoz-Couselo, Michael P. Brown, Piotr Rutkowski, Andrew Haydon, Jean-Jacques Grob, Jacob Schachter, Paola Queirolo, Luis de la Cruz-Merino, Andrew Haydon, Jean-Jacques Grob, Jacob Schachter, Paola Queirolo, Luis De La Cruz-Merino, Andre van der Westhuizen, Alexander M. Menzies, Sandra Re, Tuba Bas, Veerle de Pril, Julia Braverman, Daniel J. Tenney, Hao Tang, Georgina Long
Summary: The CheckMate 915 trial compared adjuvant nivolumab plus ipilimumab with nivolumab alone in patients with resected melanoma. The study found that there was no significant difference in recurrence-free survival between the two treatment groups.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Dermatology
Saskia Maria Schnabl, Claus Garbe, Helmut Breuninger, Vincent Walter, Valentin Aebischer, Julia Eckardt, Franziska Carola Ghoreschi, Hans-Martin Haefner, Alexander Scheu
Summary: This study aimed to investigate the risk of systemic side effects in elderly patients undergoing skin tumour surgery with tumescent local anaesthesia. The results showed that skin tumour surgery using tumescent local anaesthesia is safe for elderly patients and avoids complications caused by general anaesthesia. The incidence of systemic complications is low and is usually caused by pre-existing diseases and perioperative excitement, which can be rapidly detected and treated through monitoring.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Article
Dermatology
Stephan Forchhammer, Sonja Grunewald, Matthias Moehrle, Gisela Metzler, Thomas Eigentler, Anne-Kristin Muench, Hanna Ogrzewalla
Summary: Ex-vivo confocal laser scanning microscopy provides a rapid alternative to routine histological processing using haematoxylin and eosin-stained sections. Previous studies suggest high diagnostic accuracy in basal cell carcinoma. This study investigates the diagnostic accuracy of confocal laser scanning microscopy reporting of basal cell carcinoma in a real-life setting and compares reporting by dermatopathologists inexperienced in use of confocal laser scanning microscopy with reporting by an expert in confocal laser scanning microscopy. The results showed lower diagnostic accuracy than published data regarding artificial settings, with poor accuracy in tumor margin control. Prior knowledge of haematoxylin and eosin trained pathologists can be partially transferred to the reporting of confocal laser scanning microscopy scans; however, specific training is recommended.
ACTA DERMATO-VENEREOLOGICA
(2023)
Article
Oncology
E. Livingstone, H. Gogas, L. Kandolf-Sekulovic, F. Meier, T. K. Eigentler, M. Ziemer, P. A. M. Terheyden, A. H. Gesierich, R. A. Herbst, K. C. Kaehler, D. C. Ziogas, Z. Mijuskovic, M. Garzarolli, C. Garbe, A. Roesch, S. Ugurel, R. Gutzmer, J. J. Grob, F. Kiecker, J. Utikal, C. Windemuth-Kieselbach, S. Eckhardt, L. Zimmer, D. Schadendorf
Summary: The study aimed to investigate the efficacy of switching to atezolizumab after achieving tumor control with vemurafenib + cobimetinib in previously untreated BRAFV600-mutated melanoma patients. The results showed that early switch to atezolizumab led to rapid loss of tumor control but provided a numerical OS benefit at 2 years compared with continued targeted therapy.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Medicine, Research & Experimental
Paolo A. A. Ascierto, Christian Blank, Alexander M. M. Eggermont, Claus Garbe, Jeffrey E. E. Gershenwald, Omid Hamid, Axel Hauschild, Jason J. J. Luke, Janice M. M. Mehnert, Jeffrey A. A. Sosman, Hussein A. A. Tawbi, Mario Mandala, Alessandro Testori, Corrado Caraco, Iman Osman, Igor Puzanov
Summary: The Great Debate session at the 2022 Melanoma Bridge congress featured leading experts arguing two sides of five prominent topics in melanoma management. The debates covered choices between LAG-3 therapy or ipilimumab combined with PD-1 therapy, the acceptability of PD-1 monotherapy as a comparator arm in clinical trials, the usefulness of adjuvant treatment, the role of adjuvant therapy in stage II melanoma, and the continued role of surgery in melanoma treatment. The speakers' opinions did not necessarily align with their personal views, and the audience voted before and after each debate.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Editorial Material
Dermatology
Claus Garbe, Holger Reimann
AKTUELLE DERMATOLOGIE
(2023)
Editorial Material
Dermatology
Claus Garbe, Holger Reimann
AKTUELLE DERMATOLOGIE
(2023)
Article
Dermatology
Julia Huynh, Ulrike Leiter, Claus Garbe, Galina Shiderova, Vincent Walter, Thomas Eigentler, Alexander Scheu, Hans-Martin Haefner, Saskia Maria Schnabl
Summary: This study investigated the use of sentinel lymph node biopsy in patients with lentigo maligna melanoma and tumor thickness ≥1 mm. The results showed that sentinel lymph nodes were positive in 12.7% of cases. There was no significant difference in distant metastasis-free survival and overall survival between patients with and without sentinel lymph node biopsy.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Article
Medicine, General & Internal
Felix Peisen, Annika Gerken, Alessa Hering, Isabel Dahm, Konstantin Nikolaou, Sergios Gatidis, Thomas K. Eigentler, Teresa Amaral, Jan H. Moltz, Ahmed E. Othman
Summary: This study found that the combination of radiomics and clinical parameters did not provide additional information compared to the use of only clinical parameters in predicting the best response, progression-free survival after six months, and overall survival after six and twelve months in patients with stage IV malignant melanoma undergoing first-line targeted therapy.
Meeting Abstract
Dermatology
T. Sinnberg, H. Niessner, T. Amaral, T. Eigentler, C. Schroeder, E. S. Lindner, F. J. Hilke, I. Bonzheim, F. Fend, O. Riess, C. Garbe
EXPERIMENTAL DERMATOLOGY
(2023)
Meeting Abstract
Dermatology
H. Niessner, T. Sinnberg, T. Amaral, H. Suelberg, T. Eigentler, C. Garbe
EXPERIMENTAL DERMATOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Bilguun Nurzed, Andre Kuehne, Christoph Stefan Aigner, Sebastian Schmitter, Thoralf Niendorf, Thomas Wilhelm Eigentler
Summary: This study aims to investigate the feasibility of human cardiac MR at 14.0 T using high-density RF dipole transceiver arrays in conjunction with static and dynamic parallel transmission. The results show that both static and dynamic pTx can enhance transmission field uniformity and efficiency at 14.0 T. These findings provide a technical foundation for further exploration into CMR at 14.0 T.
MAGNETIC RESONANCE MATERIALS IN PHYSICS BIOLOGY AND MEDICINE
(2023)
Article
Oncology
Paolo A. Ascierto, Reinhard Dummer, Helen J. Gogas, Ana Arance, Mario Mandala, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsova, Ralf Gutzmer, Vanna Chiarion-Sileni, Caroline Dutriaux, Jan Willem B. de Groot, Naoya Yamazaki, Carmen Loquai, Caroline Robert, Keith T. Flaherty
Summary: The purpose of this study was to evaluate the efficacy and safety of encorafenib alone or in combination with binimetinib for the treatment of advanced BRAF(V600)-mutant melanoma. The results showed that the combination of encorafenib and binimetinib improved progression-free survival and overall response rate, and had better tolerability compared to encorafenib alone.
JOURNAL OF CLINICAL ONCOLOGY
(2023)